Finn Guo on China’s Policy in Hemophilia Care: Patients Understand Patients Best
Finn Guo, Director of Information Research at Illness Challenge Foundation, shared on LinkedIn:
”Pleased to speak at the Central China Hemophilia Joint Conference today!
Leaders from patient organizations across the country gathered together.
In China, the reimbursement barrier for hemophilia has been largely resolved.
Thanks to the multi-layered insurance mechanism, most patients have achieved “0” out-of-pocket treatment costs.
Yet several critical challenges remain:
1. Prophylactic treatment (especially regular factor prophylaxis) is still severely under-covered
2. Some innovative therapies are not yet included in the NRDL (National Reimbursement Drug List), leaving patients to pay 100% out-of-pocket
3. Gene therapy for hemophilia B, just approved in China, is still far from being truly accessible to patients
When there is a huge information gap between patients’ lived reality and policymakers, it’s hard for decision-makers to truly understand what patients go through every day—and therefore hard for them to respond with precise, impactful policies.
“Patients understand patients best.”
Our mission is to build a bridge—to translate “patient language” into “policy language,” so that government, health insurance authorities, pharmaceutical companies, and all stakeholders can truly hear, see, and feel the real situation of patients.
Under this situation, the PED is the most powerful and authentic advocacy material.”

Stay updated with Hemostasis Today.
-
Nov 24, 2025, 10:25Jean Jacques Kiladjian Visits INSERM-supervised CIC 1408 Investigation Center
-
Nov 24, 2025, 10:06Amirpasha Moetazedian Invites a PHD Student to His Lab to Explore Sustainable Artificial Blood Vessels
-
Nov 24, 2025, 09:41Kamran Hajiyev Reflects on A Week of Innovation, Collaboration, and Scientific Exchange at SVIN 2025
-
Nov 24, 2025, 02:55Do You Know Why Clot Contracts? Marin Pavlov Reflects on Expert PE Conference 2025
-
Nov 24, 2025, 01:39Ashkan Shoamanesh Shares OCEANIC-STROKE Trial’s Successful Endpoints
-
Nov 24, 2025, 01:10Swarsat K Nath on HemeNext 2025: AI is Real, Measurable, and Already Changing Lives
-
Nov 23, 2025, 15:15Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo
-
Nov 23, 2025, 14:57Jesse Landry on SeraGene Therapeutics: Rewriting the Rules of Blood and Bleeding Disorders
-
Nov 23, 2025, 14:49Reza Shojaei: What Truly Motivates Donors And What Keeps Them Coming Back?
